Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bausch Health
Biotech
Bausch Health bags phase 3-ready liver prospect in $63M buyout
Bausch Health has struck a deal to buy Durect, landing a phase 3-ready liver disease candidate that the companies believe has blockbuster potential.
Nick Paul Taylor
Jul 29, 2025 9:35am
Merck poaches marketing chief from Biogen—Chutes & Ladders
Jun 24, 2022 9:30am
Bausch Health pulls the plug on Solta Medical IPO
Jun 17, 2022 10:50am
Bausch Health files for Solta IPO as its 3-way split nears goal
Feb 9, 2022 9:30am
Bausch + Lomb files IPO for its eye care spinout
Jan 14, 2022 10:45am
Bausch-Novaliq's eye drop beats placebo again in phase 3 trial
Sep 30, 2021 11:00am
